Kairos Pharma, Ltd.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-5.4M | $-2.6M | $-1.8M |
| Depreciation & Amortization | — | — | — |
| Depreciation | — | — | — |
| Amortization | $160.0K | $160.0K | $160.0K |
| Stock-Based Compensation | — | — | — |
| Net Cash from Operating Activities | $-3.4M | $-4.0M | $81.0K |
| Investing Activities | |||
| Capital Expenditures | — | — | — |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | — | — | — |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | — | — | — |
| Net Cash from Financing Activities | $6.7M | $5.1M | $-425.0K |
| Net Change in Cash | $3.2M | $1.2M | $-344.0K |
| Free Cash Flow | — | — | — |